Skip to main content
. 2013 Aug 13;122(15):2582–2590. doi: 10.1182/blood-2012-02-407452

Figure 4.

Figure 4

Effect of administration of anti-mouse CD1d mAb on anti-blood group A titers in mice. Balb/c WT mice received intraperitoneal injection of anti-mouse CD1d mAb (n = 6). Mice that received injections of isotype-matched Ab served as the controls (n = 5). The mice were immunized with human blood group A-RBCs (5 × 108/mouse) on days 1 and 8 after mAb administration. After immunization, blood samples were obtained and the total IgM/IgG and anti-A IgM/IgG concentrations were measured using ELISA. (A-B) Treatment with anti-CD1d mAb significantly inhibited Ab production against blood group A epitopes in the mice. Anti-A IgM levels were detected 6 weeks after mAb administration, and anti-A IgG levels were detected at 8 weeks. (C-D) The kinetics of anti-A Abs in Balb/c WT mice that were injected with either anti-mouse CD1d mAb or isotype-matched Ab are shown (10× diluted serum was used). (E-F) The kinetics of the total serum immunoglobulin (IgM and IgG) levels of the Balb/c WT mice treated with anti-CD1d mAb are presented. The average values ± SEM for the individual groups are shown. *P < .05 compared with the data from WT mice treated with isotype-matched Ab.